Submitted: 04 October 2026 You are already at the latest version The spread of carbapenem-resistant Enterobacteriaceae (CRE) has weakened control of severe hospital infections. These strains evade nearly all last-resort antibiotics, making targeted β-lactamase inhibitors indispensable for β-lactam treatment. Existing carbapenem-bicyclic boronate derivative combinations show broad-spectrum activity, with confirmed efficacy against Class A serine carbapenemases represented by KPC-2.